News Articles Tagged: YHO-13177

The Future of Targeted Cancer Therapy: Insights from YHO-13177 Research

Gain insights into how research with YHO-13177 is shaping the future of targeted cancer therapy by addressing drug resistance and improving treatment efficacy.

YHO-13177 and Drug Resistance: A Focus on BCRP/ABCG2 Mechanisms

Examine the intricate relationship between YHO-13177, BCRP/ABCG2, and drug resistance, offering insights into how this inhibitor aids in overcoming therapeutic challenges.

Exploring the Market for YHO-13177: Suppliers, Pricing, and Availability for Research

A guide to navigating the market for YHO-13177, covering key suppliers, factors influencing pricing, and the importance of reliable sourcing for research purposes.

The Science Behind YHO-13177: Enhancing Cancer Drug Efficacy Through BCRP Inhibition

Delve into the scientific details of YHO-13177, a potent BCRP inhibitor, and understand how its mechanism of action directly contributes to improving cancer drug efficacy.

Unlocking Therapeutic Potential: YHO-13177 as a Key Pharmaceutical Intermediate

Discover how YHO-13177, a specific BCRP inhibitor, serves as a vital pharmaceutical intermediate in the development of new anticancer drugs targeting drug resistance.

The Role of YHO-13177 in Overcoming Chemoresistance: A Deep Dive for Researchers

Explore how YHO-13177, a potent BCRP inhibitor, is advancing research in overcoming cancer drug resistance and its implications for new therapeutic strategies.